The group’s principle activity is to translate hypoxia-activated prodrug lead compounds into marketed drugs that treat cancer. The group also invests in Alta Partners, Clarus Ventures, GBS Venture Partners (Australia), Delphi Ventures, No 8 Ventures (New Zealand), Endeavour Capital (New Zealand), Roche, and Genentech. The group operates from United States.
